Thomas Jefferson University

Robert Den

TitleAssoc Professor
InstitutionThomas Jefferson University
DepartmentRadiation Oncology
Address111 S. 11th Street
Philadelphia PA 19107
Phone215-955-6702
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shoshan Y, Gomori MJ, Moss L, Bari SE, Edery N, Den RB, Arazi L, Popovtzer A, Feldman J, Moscovici S. Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: a potential new focal therapy for brain tumors. J Neurooncol. 2025 Jan 02. PMID: 39747715.
      Citations:    
    2. Thangavel C, Boopathi E, Ciment S, Liu Y, O'Neill R, Sharma A, McMahon SB, Mellert H, Addya S, Ertel A, Birbe R, Fortina P, Dicker AP, Knudsen KE, Den RB. Correction: The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness. Clin Cancer Res. 2024 Dec 16; 30(24):5695. PMID: 39676540.
      Citations:    
    3. Wang KR, Simhal RK, Clark CB, Mann MJ, Mark JR, Lallas CD, Den R, Trabulsi EJ. Complications and Influential Perioperative Factors Associated with SpaceOAR Hydrogel Placement. Adv Urol. 2024; 2024:3439727. PMID: 39257919.
      Citations:    
    4. Furman B, Falick Michaeli T, Den R, Ben Haim S, Popovtzer A, Wygoda M, Blumenfeld P. Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease. Cancer Imaging. 2024 Jul 29; 24(1):96. PMID: 39075567.
      Citations:    
    5. Popovtzer A, Mizrachi A, D'Andrea MA, VanderWalde NA, Kurman N, Rosenfeld E, Ben-Hur R, Bellia SR, Feliciani G, Silvern D, Sarnelli A, Ballo MT, Patra P, Cohen GN, Damato AL, Shkedy Y, Den RB, Barker CA, Charas T, Hirshoren N. Extended Follow-Up Outcomes from Pooled Prospective Studies Evaluating Efficacy of Interstitial Alpha Radionuclide Treatment for Skin and Head and Neck Cancers. Cancers (Basel). 2024 Jun 24; 16(13). PMID: 39001374.
      Citations:    
    6. Blumenfeld P, Arbit E, Den R, Salhab A, Michaeli TF, Wygoda M, Hillman Y, Pfeffer RM, Fang M, Misrati Y, Weizman N, Feldman J, Popovtzer A. Correction: Real world clinical experience using daily intelligence-assisted online adaptive radiotherapy for head and neck cancer. Radiat Oncol. 2024 May 15; 19(1):57. PMID: 38750501.
      Citations:    
    7. Blumenfeld P, Arbit E, Den R, Salhab A, Falick Michaeli T, Wygoda M, Hillman Y, Pfeffer RM, Fang M, Misrati Y, Weizman N, Feldman J, Popovtzer A. Real world clinical experience using daily intelligence-assisted online adaptive radiotherapy for head and neck cancer. Radiat Oncol. 2024 Mar 30; 19(1):43. PMID: 38555453.
      Citations:    
    8. McPartland C, Salib A, Banks J, Mark JR, Lallas CD, Trabulsi EJ, Gomella LG, Goldberg H, Leiby B, Den R, Chandrasekar T. Risk of Secondary Malignancies After Pelvic Radiation: A Population-based Analysis. Eur Urol Open Sci. 2024 May; 63:52-61. PMID: 38558762.
      Citations:    
    9. Boopathi E, Den RB, Thangavel C. Innate Immune System in the Context of Radiation Therapy for Cancer. Cancers (Basel). 2023 Aug 04; 15(15). PMID: 37568788.
      Citations:    
    10. Mark JR, Gomella LG, Lallas CD, Smentkowski KE, Calvaresi A, Handley N, Den RB, Mille P, Tester WJ, Hoffman-Censits J, Dicker AP, Klonicke E, Halpern E, McCue P, Kelly WK, Trabulsi EJ. Enhancing bladder cancer care through the multidisciplinary clinic approach. Can J Urol. 2023 06; 30(3):11526-11531. PMID: 37344462.
      Citations:    
    11. Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JH, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, Tran PT, Davicioni E, Spratt DE, Attard G, Lotan TL, Lee Kiang Chua M, Sweeney CJ, Schaeffer EM. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. Cancer. 2023 Apr 14. PMID: 37060201.
      Citations:    
    12. McDonald AM, DeMora L, Yang ES, Hoyle JM, Lenzie A, Williams GR, Michalski JM, Yee D, Bahary JP, Den RB, Roach M, Dess R, Mishra MV, Valicenti RK, Lau HY, Marcrom SR, Souhami L, Mendez LC, Chen Y, Doncals DE, Pugh SL, Feng FY, Sandler HM. Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126. Cancer. 2022 Dec 29. PMID: 36579470.
      Citations:    
    13. Nishri Y, Vatarescu M, Luz I, Epstein L, Dumancic M, Del Mare S, Shai A, Schmidt M, Deutsch L, Den RB, Kelson I, Keisari Y, Arazi L, Cooks T, Domankevich V. Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts. Front Oncol. 2022; 12:888100. PMID: 36237307.
      Citations:    
    14. Boopathi E, Birbe R, Shoyele SA, Den RB, Thangavel C. Bone Health Management in the Continuum of Prostate Cancer Disease. Cancers (Basel). 2022 Sep 02; 14(17). PMID: 36077840.
      Citations:    
    15. Mare SD, Nishri Y, Shai A, Efrati M, Deutsch L, Den RB, Kelson I, Keisari Y, Domankevich V. Diffusing Alpha-Emitters Radiation Therapy Promotes a Proimmunogenic Tumor Microenvironment and Synergizes With Programmed Cell Death Protein 1 Blockade. Int J Radiat Oncol Biol Phys. 2023 Mar 01; 115(3):707-718. PMID: 36031029.
      Citations:    
    16. Kensler KH, Awasthi S, Alshalalfa M, Trock BJ, Freedland SJ, Freeman MR, You S, Mahal BA, Den RB, Dicker AP, Karnes RJ, Klein EA, Lal P, Liu Y, Davicioni E, Rayford W, Yamoah K, Rebbeck TR. Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. Eur Urol Open Sci. 2022 Jun; 40:19-26. PMID: 35638091.
      Citations:    
    17. Ramotar M, Chua MLK, Truong H, Hosni A, Pintilie M, Davicioni E, Fleshner NE, Dicker AP, Bristow RG, He HH, van der Kwast T, Den RB, Berlin A. Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. Urol Oncol. 2021 Sep 16. PMID: 34538726.
      Citations:    
    18. Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2021 Sep 01. PMID: 34481017.
      Citations:    
    19. Padilla L, Burmeister JW, Burnett OL, Covington EL, Den RB, Dominello MM, Du KL, Galavis PE, Junell S, Kahn J, Kishore M, Mooney K, Mukhopadhyay ND, Studenski MT, Yechieli RL, Fields EC. Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience. Int J Radiat Oncol Biol Phys. 2021 Nov 15; 111(4):1058-1065. PMID: 34380009.
      Citations:    
    20. Rayford W, Beksac AT, Alger J, Alshalalfa M, Ahmed M, Khan I, Falagario UG, Liu Y, Davicioni E, Spratt DE, Schaeffer EM, Feng FY, Mahal B, Nguyen PL, Den RB, Greenberger MD, Bradley R, Watson JM, Beamer M, Stamatakis L, Carmen DJ, Awasthi S, Hwang J, Weil R, Merisaari H, Mohamed N, Deane LA, Chakravarty D, Yadav KK, Yamoah K, Nair SS, Tewari AK. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun Biol. 2021 06 03; 4(1):670. PMID: 34083737.
      Citations:    
    21. Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, Karnes RJ, Trock BJ, Klein EA, Den RB, Demichelis F, Davicioni E, Sboner A, Barbieri CE. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest. 2021 05 17; 131(10). PMID: 33998599.
      Citations:    
    22. Mandigo AC, Yuan W, Xu K, Gallagher P, Pang A, Guan YF, Shafi AA, Thangavel C, Sheehan B, Bogdan D, Paschalis A, McCann JJ, Laufer TS, Gordon N, Vasilevskaya IA, Dylgjeri E, Chand SN, Schiewer MJ, Domingo-Domenech J, Den RB, Holst J, McCue PA, de Bono JS, McNair C, Knudsen KE. RB/E2F1 as a master regulator of cancer cell metabolism in advanced disease. Cancer Discov. 2021 Apr 20. PMID: 33879449.
      Citations:    
    23. Ding YC, Wu H, Davicioni E, Karnes RJ, Klein EA, Den RB, Steele L, Neuhausen SL. Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. J Transl Genet Genom. 2021; 5:50-61. PMID: 33928239.
      Citations:    
    24. Yoon J, Kim M, Posadas EM, Freedland SJ, Liu Y, Davicioni E, Den RB, Trock BJ, Karnes RJ, Klein EA, Freeman MR, You S. A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer Prostatic Dis. 2021 Feb 02. PMID: 33531653.
      Citations:    
    25. Shahait M, Liu VYT, Vapiwala N, Lal P, Kim J, Trabulsi EJ, Huang HC, Davicioni E, Thompson DJS, Spratt D, Den RB, Lee DI. Impact of Decipher on use of post-operative radiotherapy: Individual patient analysis of two prospective registries. BJUI Compass. 2021 Jul; 2(4):267-274. PMID: 35475294.
      Citations:    
    26. Smith AW, Greenberger BA, Den RB, Stock RG. Radiopharmaceuticals for Bone Metastases. Semin Radiat Oncol. 2021 Jan; 31(1):45-59. PMID: 33246636.
      Citations:    
    27. Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2020 Dec 07. PMID: 33303244.
      Citations:    
    28. Jairath NK, Dal Pra A, Vince R, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, Spratt DE. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol. 2020 Dec 05. PMID: 33293078.
      Citations:    
    29. Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW, Ross AE, Tosoian JJ, Morgan TM, Mehra R, Salami SS, Nguyen PL, Lawton CAF, Spratt DE, Feng F. Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precis Oncol. 2020 Nov; 4:1228-1238. PMID: 35050780.
      Citations:    
    30. Awasthi S, Berglund A, Abraham-Miranda J, Rounbehler RJ, Kensler K, Serna A, Vidal A, You S, Freeman MR, Davicioni E, Liu Y, Karnes RJ, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk S, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2021 Jan 01; 27(1):320-329. PMID: 33037017.
      Citations:    
    31. Sanmamed N, Glicksman RM, Herrera-Caceres J, Lehrer EJ, Heaton J, Hansen AR, Chung P, Fleshner NE, Den RB, Zaorsky NG, Berlin A. Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. Urol Oncol. 2020 Jun 15. PMID: 32553790.
      Citations:    
    32. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 Jun 09; JCO2000046. PMID: 32516092.
      Citations:    
    33. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol. 2020 May 24. PMID: 32461072.
      Citations:    
    34. Tosoian JJ, Birer SR, Jeffrey Karnes R, Zhang J, Davicioni E, Klein EE, Freedland SJ, Weinmann S, Trock BJ, Dess RT, Zhao SG, Jackson WC, Yamoah K, Pra AD, Mahal BA, Morgan TM, Mehra R, Kaffenberger S, Salami SS, Kane C, Pollack A, Den RB, Berlin A, Schaeffer EM, Nguyen PL, Feng FY, Spratt DE. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer Prostatic Dis. 2020 Mar 30. PMID: 32231245.
      Citations:    
    35. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 Mar 26. PMID: 32215583.
      Citations:    
    36. Den RB, Greenspan J, Doyle LA, Harrison AS, Peng C, Williams NL, Lallas CD, Trabulsi EJ, Gomella LG, Hurwitz MD, Leiby B, Dicker AP. A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer. Brachytherapy. 2020 Mar 23. PMID: 32217038.
      Citations:    
    37. Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E, Karnes J, Den RB, Liu Y, Davicioni E, Barbieri CE. Prognostic value of the SPOP mutant genomic subclass in prostate cancer. Urol Oncol. 2020 Mar 16. PMID: 32192889.
      Citations:    
    38. Lin J, Den RB, Greenspan J, Showalter TN, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Gomella LG, Hurwitz MD, Leiby B, Dicker AP, Kelly WK. Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 Feb 03. PMID: 32029346.
      Citations:    
    39. Moore A, Den RB, Popovtzer A, Goldvaser H, Gordon N, Goldstein DA. Fractionation scheme and treatment planning method for early glottic cancer in the United States: Economic impact of different medical decisions. Head Neck. 2020 Jan 24. PMID: 31976607.
      Citations:    
    40. Greenberger BA, Taylor JM, Chen VE, Den RB. Comparing Radiotherapy to Prostatectomy for High-Risk Prostate Cancer: A Narrative Review of Mortality and Quality-of-Life Outcomes. Cancer J. 2020 Jan/Feb; 26(1):29-37. PMID: 31977382.
      Citations:    
    41. Javed E, Thangavel C, Frara N, Singh J, Mohanty I, Hypolite J, Birbe R, Braverman AS, Den RB, Rattan S, Zderic SA, Deshpande DA, Penn RB, Ruggieri MR, Chacko S, Boopathi E. Increased expression of desmin and vimentin reduces bladder smooth muscle contractility via JNK2. FASEB J. 2019 Dec 16. PMID: 31909533.
      Citations:    
    42. Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2019 Dec 12; JCO1902768. PMID: 31829902.
      Citations:    
    43. Greenberger BA, Zaorsky NG, Den RB. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2019 Dec 05. PMID: 31813810.
      Citations:    
    44. Greenberger BA, Chen VE, Den RB. Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions. Front Oncol. 2019; 9:1273. PMID: 31850194.
      Citations:    
    45. Marascio J, Spratt DE, Zhang J, Trabulsi EJ, Le T, Sedzorme WS, Beeler WH, Davicioni E, Dabbas B, Lin DW, Gore JL, Bloom M, Mann M, Mark JR, Calvaresi A, Godwin JL, McCue P, Hurwitz MD, Kelly WK, Lallas CD, Knudsen KE, Gomella LG, Dicker AP, Den RB. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis. 2019 Nov 12. PMID: 31719663.
      Citations:    
    46. Lin J, Song AJ, Hoffman-Censits J, Leiby BE, Tuluc M, Shaw C, Harshyne L, Kean R, Bar-Ad V, Den RB, Hurwitz MD, Louie J, Philipose S, Deshmukh SP, Johnson JM, Dicker AP, Hooper DC, Kelly WK, Lu B. A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer. Am J Clin Oncol. 2019 Nov 05. PMID: 31693508.
      Citations:    
    47. Fernandez C, Papanagnou D, Kushner M, Leiby BE, Den RB. Feasibility and Impact of Emotional Intelligence Evaluation in Radiation Oncology Residency Interviews. J Am Coll Radiol. 2019 Oct 19. PMID: 31639361.
      Citations:    
    48. Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, D'Amico AV, Kantoff PW, Bradner JE, Mucci LA, Chavarro JE, Loda M, Brown M. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019 Sep 25; 10(1):4358. PMID: 31554818.
      Citations:    
    49. Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM. Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment naïve primary prostate cancer. Clin Cancer Res. 2019 Sep 12. PMID: 31515456.
      Citations:    
    50. Rasool RU, Natesan R, Deng Q, Aras S, Lal P, Sander Effron S, Mitchell-Velasquez E, Posimo JM, Carskadon S, Baca SC, Pomerantz MM, Siddiqui J, Schwartz LE, Lee DJ, Palanisamy N, Narla G, Den RB, Freedman ML, Brady DC, Asangani IA. CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation. Cancer Discov. 2019 Aug 29. PMID: 31466944.
      Citations:    
    51. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2019 Aug 27. PMID: 31455846.
      Citations:    
    52. Fernandez C, Lopez BL, Kushner M, Leiby BE, Den RB. Overemphasis of Step 1 Scores May Impact Application Pool Diversity in Radiation Oncology. Pract Radiat Oncol. 2019 Jul 29. PMID: 31369886.
      Citations:    
    53. Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K. African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. J Urol. 2019 08; 202(2):247-255. PMID: 31107158.
      Citations:    
    54. Moore A, Den RB, Gordon N, Sarfaty M, Kundel Y, Brenner B, Goldstein DA. The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States. Clin Colorectal Cancer. 2019 Sep; 18(3):209-217. PMID: 31255477.
      Citations:    
    55. Alshalalfa M, Liu Y, Wyatt AW, Gibb EA, Tsai HK, Erho N, Lehrer J, Takhar M, Ramnarine VR, Collins CC, Den RB, Schaeffer EM, Davicioni E, Lotan TL, Bismar TA. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. Int J Cancer. 2019 May 24. PMID: 31125117.
      Citations:    
    56. Den RB, George D, Pieczonka C, McNamara M. Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection. Am J Clin Oncol. 2019 Mar 04. PMID: 30844849.
      Citations:    
    57. Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. 2019 Feb 12. PMID: 30773341.
      Citations:    
    58. Thangavel C, Gomes CM, Zderic SA, Javed E, Addya S, Singh J, Das S, Birbe R, Den RB, Rattan S, Deshpande DA, Penn RB, Chacko S, Boopathi E. NF-?B and GATA-6 Repress Transcription of Caveolins in Bladder Smooth Muscle Hypertrophy. Am J Pathol. 2019 Jan 29. PMID: 30707892.
      Citations:    
    59. Van den Broeck T, Moris L, Gevaert T, Tosco L, Smeets E, Fishbane N, Liu Y, Helsen C, Margrave J, Buerki C, Davicioni E, Van Poppel H, Everaerts W, Weinmann S, Den R, Davis J, Schaeffer E, Karnes RJ, Claessens F, Joniau S. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. Eur Urol Oncol. 2019 Jan 10. PMID: 31411980.
      Citations:    
    60. Moore A, Stav I, Den RB, Gordon N, Sarfaty M, Neiman V, Rosenbaum E, Goldstein DA. The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States. J Oncol. 2019; 2019:8170428. PMID: 30719039.
      Citations:    
    61. Trager M, Greenberger B, Harrison AS, Keller J, Den RB. SpaceOAR to improve dosimetric outcomes for monotherapy high-dose-rate prostate implantation in a patient with ulcerative colitis. J Contemp Brachytherapy. 2018 Dec; 10(6):577-582. PMID: 30662483.
      Citations:    
    62. Goldstein DA, Den RB. Patient-Centered Oncology or Population-Centered Oncology-Which Do We Want, and Which Tradeoffs Are We Willing To Accept? Oncologist. 2019 Mar; 24(3):288-290. PMID: 30523149.
      Citations:    
    63. Miyahira AK, Den RB, Carlo MI, de Leeuw R, Hope TA, Karzai F, McKay RR, Salami SS, Simons JW, Pienta KJ, Soule HR. Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2019 Feb; 79(3):244-258. PMID: 30381857.
      Citations:    
    64. Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer Prostatic Dis. 2018 Oct 26. PMID: 30367117.
      Citations:    
    65. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2018 Oct 13. PMID: 30321406.
      Citations:    
    66. Hubley E, Shukla G, Vakhnenko Y, Den RB, Harrison AS. Avoidance sectors to reduce dosimetric impact of an irreproducible pannus on setup uncertainty in prostate SBRT VMAT: A case study. Med Dosim. 2018 Aug 14. PMID: 30119882.
      Citations:    
    67. Truong H, Savard C, Den RB, Ryan Mark J. Radiation effect on male spermatogenesis and fertility - the science and ethical consideration of the Oregon and Washington radiation experiments on prison inmates. Urology. 2018 Aug 11. PMID: 30107187.
      Citations:    
    68. Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precis Oncol. 2018; 2018. PMID: 30761387.
      Citations:    
    69. Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clin Cancer Res. 2018 May 14. PMID: 29760221.
      Citations:    
    70. Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, Den RB, Jeffrey Karnes R, Klein E, Hoskin PJ, Freedland SJ, Lamb AD, Neal DE, Buffa FM, Bristow RG, Boutros PC, Davicioni E, Choudhury A, West CML. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine. 2018 May; 31:182-189. PMID: 29729848.
      Citations:    
    71. Thangavel C, Perepelyuk M, Boopathi E, Liu Y, Polischak S, Deshpande DA, Rafiq K, Dicker AP, Knudsen KE, Shoyele SA, Den RB. Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. Mol Pharm. 2018 Apr 04. PMID: 29616555.
      Citations:    
    72. Logothetis C, Morris MJ, Den R, Coleman RE. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev. 2018 Mar; 37(1):189-196. PMID: 29380085.
      Citations:    
    73. Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 Feb 22. PMID: 29478736.
      Citations:    
    74. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol. 2018 Jan 25; e175230. PMID: 29372236.
      Citations:    
    75. Thangavel C, Boopathi E, Liu Y, McNair C, Haber A, Perepelyuk M, Bhardwaj A, Addya S, Ertel A, Shoyele S, Birbe R, Salvino JM, Dicker AP, Knudsen KE, Den RB. Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 Mar 15; 24(6):1402-1414. PMID: 29311118.
      Citations:    
    76. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 01; 36(4):414-424. PMID: 29236593.
      Citations:    
    77. Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Eur Urol. 2017 Dec 10. PMID: 29233664.
      Citations:    
    78. Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2018 Feb 20; 36(6):581-590. PMID: 29185869.
      Citations:    
    79. Den RB, Folino M, Dicker AP. Utilizing 10-Year Results From the American Board of Radiology Clinical Examination to Identify Areas for Programmatic Improvement. Int J Radiat Oncol Biol Phys. 2018 Mar 01; 100(3):556-557. PMID: 29413270.
      Citations:    
    80. Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. Eur Urol. 2017 Nov 09. PMID: 29128208.
      Citations:    
    81. Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clin Cancer Res. 2017 Nov 15; 23(22):7072-7083. PMID: 28899973.
      Citations:    
    82. Williams NL, Dan T, Zaorsky NG, Garg S, Den RB. The Role of Genomic Techniques in Predicting Response to Radiation Therapy. Oncology (Williston Park). 2017 07 15; 31(7):562-70. PMID: 28712100.
      Citations:    
    83. Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol. 2017 May 19. PMID: 28533151.
      Citations:    
    84. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 May 11. PMID: 28494073.
      Citations:    
    85. Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LLC, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng FY. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J Clin Oncol. 2017 Jun 20; 35(18):1991-1998. PMID: 28358655.
      Citations:    
    86. Dalela D, Santiago-Jiménez M, Yousefi K, Karnes RJ, Ross AE, Den RB, Freedland SJ, Schaeffer EM, Dicker AP, Menon M, Briganti A, Davicioni E, Abdollah F. Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. J Clin Oncol. 2017 Jun 20; 35(18):1982-1990. PMID: 28350520.
      Citations:    
    87. Mo F, Lin D, Takhar M, Ramnarine VR, Dong X, Bell RH, Volik SV, Wang K, Xue H, Wang Y, Haegert A, Anderson S, Brahmbhatt S, Erho N, Wang X, Gout PW, Morris J, Karnes RJ, Den RB, Klein EA, Schaeffer EM, Ross A, Ren S, Sahinalp SC, Li Y, Xu X, Wang J, Wang J, Gleave ME, Davicioni E, Sun Y, Wang Y, Collins CC. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. Eur Urol. 2017 Mar 19. PMID: 28330676.
      Citations:    
    88. Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jiménez M, Erho N, Jordan J, Yousefi K, Lam LLC, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, Den RB, Freedland SJ, Davicioni E, Klein EA, Schalken JA. Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget. 2017 Aug 01; 8(31):50804-50813. PMID: 28881605.
      Citations:    
    89. Kim H, Kalchman I, Santiago-Jiménez M, Lehrer J, Guo J, Hermann G, Yamoah K, Alshalalfa M, Huang HC, Ross AE, Schaeffer EM, Davicioni E, Erho N, Yousefi K, Den RB. Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. Cancer. 2017 Jun 15; 123(12):2240-2247. PMID: 28140459.
      Citations:    
    90. Perepelyuk M, Shoyele O, Birbe R, Thangavel C, Liu Y, Den RB, Snook AE, Lu B, Shoyele SA. siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. Mol Ther Nucleic Acids. 2017 Mar 17; 6:259-268. PMID: 28325292.
      Citations:    
    91. Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubeidi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA. MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. Cancer Res. 2017 Feb 15; 77(4):1021-1034. PMID: 28011622.
      Citations:    
    92. Kim H, Malatesta TM, Anné PR, McAna J, Bar-Ad V, Dicker AP, Den RB. Increasing faculty participation in resident education and providing cost-effective self-assessment module credit to faculty through resident-generated didactics. Pract Radiat Oncol. 2017 Jul - Aug; 7(4):241-245. PMID: 28132850.
      Citations:    
    93. Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment S, Cotzia P, Dean JL, Snook AE, McNair C, Price MA, Hernandez JR, Zhao SG, Birbe R, McCarthy JB, Turely EA, Pienta KJ, Feng FY, Dicker AP, Knudsen KE, Den RB. RB loss promotes prostate cancer metastasis. Cancer Res. 2016 Dec 06. PMID: 27923835.
      Citations:    
    94. Doyle LA, Yondorf M, Peng C, Harrison AS, Den RB. Process Mapping and Time Study to Improve Efficiency of New Procedure Implementation for High-Dose Rate Prostate Brachytherapy. J Healthc Qual. 2016 Nov 01. PMID: 27811578.
      Citations:    
    95. Kim H, Skowronski J, Den RB. Prognostic outlier genes for enhanced prostate cancer treatment. Future Oncol. 2016 Oct 12. PMID: 27728977.
      Citations:    
    96. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016 Oct 12. PMID: 27743920.
      Citations:    
    97. Raval A, Dan TD, Williams NL, Pridjian A, Den RB. Radioisotopes in management of metastatic prostate cancer. Indian J Urol. 2016 Oct-Dec; 32(4):277-281. PMID: 27843209.
      Citations:    
    98. Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng FY, Schaeffer EM, Trabulsi EJ, Gomella LG, Hurwitz MD, Dicker AP, Den RB. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urol Case Rep. 2016 Nov; 9:51-54. PMID: 27713863.
      Citations:    
    99. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 Sep 3. PMID: 27745980.
      Citations:    
    100. Klein EA, Santiago-Jiménez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, Freedland SJ, Ross AE. Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. J Urol. 2016 Aug 26. PMID: 27569435.
      Citations:    
    101. Lobo JM, Trifiletti DM, Sturz VN, Dicker AP, Buerki C, Davicioni E, Cooperberg MR, Karnes RJ, Jenkins RB, Den RB, Showalter TN. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. Clin Genitourin Cancer. 2017 Jun; 15(3):e299-e309. PMID: 28089723.
      Citations:    
    102. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Aug 15. PMID: 27528718.
      Citations:    
    103. Zaorsky NG, Egleston BL, Horwitz EM, Dicker AP, Nguyen PL, Showalter TN, Den RB. The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer. Am J Clin Oncol. 2016 Aug; 39(4):321-6. PMID: 27322694.
      Citations:    
    104. Zaorsky NG, Ricco AG, Churilla TM, Horwitz EM, Den RB. ASTRO APEx® and RO-ILS™ are applicable to medical malpractice in radiation oncology. Future Oncol. 2016 Nov; 12(22):2643-2657. PMID: 27470145.
      Citations:    
    105. White NM, Zhao SG, Zhang J, Rozycki EB, Dang HX, McFadden SD, Eteleeb AM, Alshalalfa M, Vergara IA, Erho N, Arbeit JM, Karnes RJ, Den RB, Davicioni E, Maher CA. Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. Eur Urol. 2016 Jul 22. PMID: 27460352.
      Citations:    
    106. Myers RE, Leader AE, Censits JH, Trabulsi EJ, Keith SW, Petrich AM, Quinn AM, Den RB, Hurwitz MD, Lallas CD, Hegarty SE, Dicker AP, Zeigler-Johnson CM, Giri VN, Ayaz H, Gomella LG. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study. J Cancer Educ. 2016 Jul 15. PMID: 27418065.
      Citations:    
    107. You S, Knudsen BS, Erho N, Alshalalfa M, Takhar M, Al-Deen Ashab H, Davicioni E, Karnes RJ, Klein EA, Den RB, Ross AE, Schaeffer EM, Garraway IP, Kim J, Freeman MR. Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Res. 2016 Sep 1; 76(17):4948-58. PMID: 27302169.
      Citations:    
    108. Dan TD, Doyle L, Raval AJ, Pridjian A, Gomella LG, Den RB. Dosing, administration, and safety of radium-223: How I do it. Can J Urol. 2016 Jun; 23(3):8301-5. PMID: 27347625.
      Citations:    
    109. Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol. 2016 Apr 1; 2(4):471-80. PMID: 26746117.
      Citations:    
    110. Zaorsky NG, Keith SW, Shaikh T, Nguyen PL, Horwitz EM, Dicker AP, Den RB. Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. Am J Clin Oncol. 2016 Mar 24. PMID: 27014930.
      Citations:    
    111. Freedland SJ, Den RB. Reply to Nicola Fossati, Giorgio Gandaglia, Alberto Bossi, Francesco Montorsi, Alberto Briganti's Letter to the Editor re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy After Radical Prostatectomy. Eur Urol 2016;70:588-96. Eur Urol. 2016 Oct; 70(4):e110-e111. PMID: 26992279.
      Citations:    
    112. Perepelyuk M, Thangavel C, Liu Y, Den RB, Lu B, Snook AE, Shoyele SA. Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model. Mol Ther Nucleic Acids. 2016; 5:e282. PMID: 26812654.
      Citations:    
    113. Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng FY, Davicioni E, Dicker AP, Karnes RJ, Den RB. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol. 2016 Oct; 70(4):588-596. PMID: 26806658.
      Citations:    
    114. Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. PMID: 26771938.
      Citations:    
    115. Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90. PMID: 26972640.
      Citations:    
    116. Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng FY. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clin Cancer Res. 2016 Apr 1; 22(7):1777-86. PMID: 26631616.
      Citations:    
    117. Kim H, Malatesta TM, Simone NL, Den RB, McAna J, Dicker AP, Bar Ad V. A single activity with a practice quality improvement project for faculty and a quality improvement project for residents. Pract Radiat Oncol. 2016 Mar-Apr; 6(2):114-8. PMID: 26723550.
      Citations:    
    118. Miyahira AK, Lang JM, Den RB, Garraway IP, Lotan TL, Ross AE, Stoyanova T, Cho SY, Simons JW, Pienta KJ, Soule HR. Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2016 Feb; 76(2):125-39. PMID: 26477609.
      Citations:    
    119. Faisal FA, Sundi D, Tosoian JJ, Choeurng V, Alshalalfa M, Ross AE, Klein E, Den R, Dicker A, Erho N, Davicioni E, Lotan TL, Schaeffer EM. Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. Eur Urol. 2016 Jul; 70(1):14-7. PMID: 26443432.
      Citations:    
    120. Dim N, Perepelyuk M, Gomes O, Thangavel C, Liu Y, Den R, Lakshmikuttyamma A, Shoyele SA. Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation. J Nanobiotechnology. 2015; 13(1):61. PMID: 26410728.
      Citations:    
    121. Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol. 2015 Sep 1; 33(25):2789-96. PMID: 26195723.
      Citations:    
    122. Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell. 2015 Jul 13; 28(1):97-113. PMID: 26175416.
      Citations:    
    123. Lawrence YR, Samueli B, Levitin R, Pail O, Spieler B, Pfeffer R, Goldstein J, Den RB, Symon Z. Do Prostate Cancer Patients With Markedly Elevated PSA Benefit From Radiation Therapy?: A Population-based Study. Am J Clin Oncol. 2015 Jun 29. PMID: 26125304.
      Citations:    
    124. Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol. 2015 Jun; 115(3):295-300. PMID: 26028229.
      Citations:    
    125. Srinivasan A, Thangavel C, Liu Y, Shoyele S, Den RB, Selvakumar P, Lakshmikuttyamma A. Quercetin regulates ß-catenin signaling and reduces the migration of triple negative breast cancer. Mol Carcinog. 2015 May 12. PMID: 25968914.
      Citations:    
    126. Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY. Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. Eur Urol. 2015 Oct; 68(4):555-67. PMID: 25964175.
      Citations:    
    127. Lobo JM, Dicker AP, Buerki C, Daviconi E, Karnes RJ, Jenkins RB, Patel N, Den RB, Showalter TN. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. PLoS One. 2015; 10(3):e0116866. PMID: 25837660.
      Citations:    
    128. Dan TD, Eldredge-Hindy HB, Hoffman-Censits J, Lin J, Kelly WK, Gomella LG, Lallas CD, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. Am J Clin Oncol. 2015 Feb 25. PMID: 25723740.
      Citations:    
    129. de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, Kelly WK, Trabulsi EJ, Lallas CD, Gomella LG, Knudsen KE. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015 Feb 15; 21(4):795-807. PMID: 25691773.
      Citations:    
    130. Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015 Mar 10; 33(8):944-51. PMID: 25667284.
      Citations:    
    131. Mishra MV, Scher ED, Andrel J, Margules AC, Hegarty SE, Trabulsi EJ, Hyslop T, Den RB, Lallas CD, Gomella LG, Dicker AP, Showalter TN. Adjuvant Versus Salvage Radiation Therapy for Prostate Cancer Patients With Adverse Pathologic Features: Comparative Analysis of Long-term Outcomes. Am J Clin Oncol. 2015 Feb; 38(1):55-60. PMID: 24051934.
      Citations:    
    132. Zaorsky NG, Hurwitz MD, Dicker AP, Showalter TN, Den RB. Is robotic arm stereotactic body radiation therapy 'virtual high-dose rate brachytherapy' effective for prostate cancer? An analysis of comparative effectiveness using published data. Expert Rev Med Devices. 2015 May; 12(3):317-27. PMID: 25540018.
      Citations:    
    133. Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014 Dec; 15(13):1469-80. PMID: 25456366.
      Citations:    
    134. Den RB, Kelly WK. Effect of docetaxel on safety and efficacy of radium-223. Lancet Oncol. 2014 Nov; 15(12):1292-3. PMID: 25439686.
      Citations:    
    135. Lallas CD, Fashola Y, Den RB, Gelpi-Hammerschmidt F, Calvaresi AE, McCue P, Birbe R, Gomella LG, Trabulsi EJ. Predictors of positive surgical margins after radical prostatectomy at a single institution: preoperative and pathologic factors, and the impact of surgeon variability and technique on incidence and location. Can J Urol. 2014 Oct; 21(5):7479-86. PMID: 25347375.
      Citations:    
    136. Eldredge-Hindy HB, Eastwick G, Anne PR, Rosenblum NG, Schilder RJ, Chalian R, Zibelli AM, Kim CH, Den R. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer. J Contemp Brachytherapy. 2014 Oct; 6(3):262-70. PMID: 25337127.
      Citations:    
    137. Augello MA, Den RB, Knudsen KE. AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev. 2014 Sep; 33(2-3):399-411. PMID: 24425228.
      Citations:    
    138. Thangavel C, Boopathi E, Ciment S, Liu Y, O' Neill R, Sharma A, McMahon SB, Mellert H, Addya S, Ertel A, Birbe R, Fortina P, Dicker AP, Knudsen KE, Den RB. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness. Clin Cancer Res. 2014 Nov 1; 20(21):5468-82. PMID: 25165096.
      Citations:    
    139. Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Aug 1; 89(5):1038-46. PMID: 25035207.
      Citations:    
    140. Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. Brachytherapy. 2014 Sep-Oct; 13(5):456-64. PMID: 24953945.
      Citations:    
    141. Den RB, Doyle LA, Knudsen KE. Practical guide to the use of radium 223 dichloride. Can J Urol. 2014 Apr; 21(2 Supp 1):70-6. PMID: 24775727.
      Citations:    
    142. Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, Showalter TN, Hurwitz MD, Dicker AP, Den RB. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncol. 2014 Feb; 10(3):457-74. PMID: 24559451.
      Citations:    
    143. Zaorsky NG, Doyle LA, Hurwitz MD, Dicker AP, Den RB. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer? Expert Rev Anticancer Ther. 2014 Jan; 14(1):39-50. PMID: 24124755.
      Citations:    
    144. Mishra MV, Shen X, Den RB, Champ CE, Trabulsi EJ, Lallas CD, Gomella LG, Dicker AP, Showalter TN. Patterns of Care for Elderly Men Diagnosed With Favorable-risk Prostate Cancer From 2004 to 2008: A Population-based Analysis. Am J Clin Oncol. 2013 Dec; 36(6):606-11. PMID: 22892435.
      Citations:    
    145. Zaorsky NG, Den RB, Doyle LA, Dicker AP, Hurwitz MD. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. Expert Rev Med Devices. 2013 Nov; 10(6):751-63. PMID: 24195459.
      Citations:    
    146. Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. High dose rate brachytherapy boost for prostate cancer: A systematic review. Cancer Treat Rev. 2014 Apr; 40(3):414-25. PMID: 24231548.
      Citations:    
    147. Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, Ma T, Den RB, Dicker AP, Feng FY, Knudsen KE. A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult. Cancer Discov. 2013 Nov; 3(11):1254-71. PMID: 24027197.
      Citations:    
    148. Zaorsky NG, Harrison AS, Trabulsi EJ, Gomella LG, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol. 2013 Oct; 10(10):565-79. PMID: 24018567.
      Citations:    
    149. Zaorsky NG, Siglin J, Den RB, Keith SW, Showalter TN, Dicker AP, Bar-Ad V. The responsibilities of a chief resident in radiation oncology: results of a national survey. Int J Radiat Oncol Biol Phys. 2013 Nov 1; 87(3):460-1. PMID: 23906932.
      Citations:    
    150. Zaorsky NG, Trabulsi EJ, Lin J, Den RB. Multimodality therapy for patients with high-risk prostate cancer: current status and future directions. Semin Oncol. 2013 Jun; 40(3):308-21. PMID: 23806496.
      Citations:    
    151. Zaorsky NG, Raj GV, Trabulsi EJ, Lin J, Den RB. The dilemma of a rising prostate-specific antigen level after local therapy: what are our options? Semin Oncol. 2013 Jun; 40(3):322-36. PMID: 23806497.
      Citations:    
    152. Lawrence YR, Glass C, Symon Z, Dicker AP, Den RB. Phase I trials involving radiation therapy, quantifying the risks. J Med Imaging Radiat Oncol. 2013 Dec; 57(6):719-24. PMID: 24283562.
      Citations:    
    153. Giacalone NJ, Den RB, Eisenberg R, Chen H, Olson SJ, Massion PP, Carbone DP, Lu B. ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma. Future Oncol. 2013 May; 9(5):737-45. PMID: 23647301.
      Citations:    
    154. Zaorsky NG, Malatesta TM, Showalter TN, Den RB, Shi W, Anne PR, Werner-Wasik M, Dicker AP, Bar-Ad V. Impact of a radiation oncology elective on the careers of young physicians: update on a prospective cohort study. Int J Radiat Oncol Biol Phys. 2013 Jun 1; 86(2):214-5. PMID: 23498775.
      Citations:    
    155. Buzurovic I, Showalter TN, Studenski MT, Den RB, Dicker AP, Cao J, Xiao Y, Yu Y, Harrison A. Commissioning and implementation of an implantable dosimeter for radiation therapy. J Appl Clin Med Phys. 2013; 14(2):3989. PMID: 23470929.
      Citations:    
    156. Zaorsky NG, Ohri N, Showalter TN, Dicker AP, Den RB. Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev. 2013 Nov; 39(7):728-36. PMID: 23453861.
      Citations:    
    157. Gutovich JM, Den RB, Werner-Wasik M, Dicker AP, Lawrence YR. Predictors of radiation oncology resident research productivity. J Am Coll Radiol. 2013 Mar; 10(3):185-9. PMID: 23246134.
      Citations:    
    158. Zaorsky NG, Studenski MT, Dicker AP, Gomella L, Den RB. Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care? Cancer Treat Rev. 2013 May; 39(3):212-8. PMID: 23218442.
      Citations:    
    159. Ohri N, Shen X, Den RB, Dicker AP, Trabulsi EJ, Showalter TN. Salvage radiotherapy for prostate cancer: Finding a way forward using radiobiological modeling. Cancer Biol Ther. 2012 Dec 1; 13(14):1449-53. PMID: 22954697.
      Citations:    
    160. Ohri N, Den R, Showalter TN. In regard to Yeoh et al. Int J Radiat Oncol Biol Phys. 2012 Sep 1; 84(1):4; author reply 4-5. PMID: 22901415.
      Citations:    
    161. Zaorsky NG, Malatesta TM, Den RB, Wuthrick E, Ahn PH, Werner-Wasik M, Shi W, Dicker AP, Anne PR, Bar-Ad V, Showalter TN. Assessing the value of an optional radiation oncology clinical rotation during the core clerkships in medical school. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e465-9. PMID: 22704704.
      Citations:    
    162. Den RB, Lu B. Heat shock protein 90 inhibition: rationale and clinical potential. Ther Adv Med Oncol. 2012 Jul; 4(4):211-8. PMID: 22754594.
      Citations:    
    163. Den RB, Nowak K, Buzurovic I, Cao J, Harrison AS, Lawrence YR, Dicker AP, Showalter TN. Implanted dosimeters identify radiation overdoses during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 1; 83(3):e371-6. PMID: 22633553.
      Citations:    
    164. Den RB, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, Lawrence YR, Hegarty S, Hyslop T, Andrews DW, Glass J, Friedman DP, Green MR, Camphausen K, Dicker AP. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 2013 Feb 1; 85(2):321-8. PMID: 22687197.
      Citations:    
    165. Schiewer MJ, Den R, Hoang DT, Augello MA, Lawrence YR, Dicker AP, Knudsen KE. mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer. 2012 Feb; 19(1):1-12. PMID: 21903859.
      Citations:    
    166. Den RB, Andrews DW. Combined role of whole-brain radiation therapy and radiosurgery for the treatment of brain metastasis. Prog Neurol Surg. 2012; 25:228-35. PMID: 22236684.
      Citations:    
    167. Mishra MV, Champ CE, Den RB, Scher ED, Shen X, Trabulsi EJ, Lallas CD, Knudsen KE, Dicker AP, Showalter TN. Postprostatectomy radiation therapy: an evidence-based review. Future Oncol. 2011 Dec; 7(12):1429-40. PMID: 22112318.
      Citations:    
    168. Aparicio A, Den RB, Knudsen KE. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol. 2011 Oct; 8(10):562-8. PMID: 21811228.
      Citations:    
    169. Den RB, Andrews DW. Radiotherapy for brain metastases. Neurosurg Clin N Am. 2011 Jan; 22(1):37-44, vi. PMID: 21109147.
      Citations:    
    170. Den RB, Doemer A, Kubicek G, Bednarz G, Galvin JM, Keane WM, Xiao Y, Machtay M. Daily image guidance with cone-beam computed tomography for head-and-neck cancer intensity-modulated radiotherapy: a prospective study. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1353-9. PMID: 19540071.
      Citations:    
    171. Andrews DW, Werner-Wasik M, Den RB, Paek SH, Downes-Phillips B, Willcox TO, Bednarz G, Maltenfort M, Evans JJ, Curran WJ. Toward dose optimization for fractionated stereotactic radiotherapy for acoustic neuromas: comparison of two dose cohorts. Int J Radiat Oncol Biol Phys. 2009 Jun 1; 74(2):419-26. PMID: 19042095.
      Citations:    
    172. Allen AM, Den R, Wong JS, Zurakowski D, Soto R, Jänne PA, Zellos L, Bueno R, Sugarbaker DJ, Baldini EH. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys. 2007 Aug 1; 68(5):1366-74. PMID: 17674974.
      Citations:    
    173. Tengs T, LaFramboise T, Den RB, Hayes DN, Zhang J, DebRoy S, Gentleman RC, O'Neill K, Birren B, Meyerson M. Genomic representations using concatenates of Type IIB restriction endonuclease digestion fragments. Nucleic Acids Res. 2004; 32(15):e121. PMID: 15329383.
      Citations:    
    Den's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (129)
    Explore
    _
    Co-Authors (84)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _